Cowen Downgrades Alimera Sciences (ALIM) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St set to open higher as chip stocks extend recovery; earnings in focus
- Oil prices rise nearly 2% on fresh attacks by US and Iran
- Chip stocks extend global rebound following last week's rout
- Citi's Chew says U.S. stock positioning unwind may not be over
- Adobe, Salesforce and Intuit fall as Morgan Stanley begins cautious coverage
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
Alimera Sciences Announces First Quarter 2016 Financial Results
May 4, 2016 4:23 PM EDTFirst quarter revenue improved 49% compared to first quarter 2015 due to increasing ILUVIEN® sales in the U.S.Record benefit investigations in the first quarter indicate increasing physician demandOver 5,000 eyes treated with ILUVIEN® in four primary marketsAlimera to host conference call on May 5, 2016 at 10:00 AM ET
ATLANTA, May 04, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of... More
